


**DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)**

**Derbyshire commissioning guidance for the treatment of Ankylosing Spondylitis and non-radiographic axial spondyloarthritis (nrAS) June 2018**



NICE approved treatment

Local variation to NICE

**The CCG's will only commission 3 switches per patient - this includes treatment failure and contra-indication/intolerance**

Dosing schedule

Biologic		Ankylosing Spondylitis (AS)			Non radiographic axial spondyloarthritis (nrAS)			Response measured
		NICE TA	Loading dose	Maintenance dose	NICE TA	Loading dose	Maintenance dose	
<b>Subcutaneous preparations</b>				<b>Subcutaneous preparations</b>				
Adalimumab (SC)	Monoclonal antibodies	TA383	40mg every 2 weeks	NA	TA383	40mg every 2 weeks	NA	12 Weeks
Etanercept (SC)	Recombinant human TNF receptor fusion protein	TA383	50mg once weekly Or 25mg twice weekly	NA	TA383	50mg once weekly	NA	12 weeks
Golimumab (SC)	Monoclonal antibody	TA475	50mg every month  >100kg in body weight, (& disease does not respond after 4x50mg doses), increase dose to 100mg every month.	NA	TA497	50mg every month  >100kg in body weight, (& disease does not respond after 4x50mg doses), increase dose to 100mg every month	NA	12-14 weeks
Certolizumab (SC)	Monoclonal antibody	TA383	400mg (2x 200mg) given at Week 0, 2 & 4	200mg every 2 weeks or 400mg every 4 weeks	TA383	400mg (2x 200mg) given at Week 0, 2 & 4	200mg every 2 weeks or 400mg every 4 weeks	12 weeks
Secukinumab (SC)	Human monoclonal antibody selective for IL-17A	TA407	Week 0,1,2 & 3 – 150mg	Week 4 – 150mg & then continue every month.	--	--	--	16 weeks
<b>Intravenous infusion</b>								
Infliximab (IV)	Monoclonal antibodies	TA383	5mg/kg IV at week 0, 2 & 6	5mg/kg IV every 6-8 weeks thereafter	--	--	--	6 weeks